<?xml version="1.0" ?><!DOCTYPE PubmedArticleSet PUBLIC "-//NLM//DTD PubMedArticle, 1st June 2018//EN" "https://dtd.nlm.nih.gov/ncbi/pubmed/out/pubmed_180601.dtd"><PubmedArticleSet><PubmedArticle>    <MedlineCitation Status="In-Data-Review" Owner="NLM">        <PMID Version="1">30458861</PMID>        <DateRevised>            <Year>2018</Year>            <Month>11</Month>            <Day>21</Day>        </DateRevised>        <Article PubModel="Electronic">            <Journal>                <ISSN IssnType="Electronic">1465-542X</ISSN>                <JournalIssue CitedMedium="Internet">                    <Volume>20</Volume>                    <Issue>1</Issue>                    <PubDate>                        <Year>2018</Year>                        <Month>Nov</Month>                        <Day>20</Day>                    </PubDate>                </JournalIssue>                <Title>Breast cancer research : BCR</Title>                <ISOAbbreviation>Breast Cancer Res.</ISOAbbreviation>            </Journal>            <ArticleTitle>Cleavage of the extracellular domain of junctional adhesion molecule-A is associated with resistance to anti-HER2 therapies in breast cancer settings.</ArticleTitle>            <Pagination>                <MedlinePgn>140</MedlinePgn>            </Pagination>            <ELocationID EIdType="doi" ValidYN="Y">10.1186/s13058-018-1064-1</ELocationID>            <Abstract>                <AbstractText Label="BACKGROUND" NlmCategory="BACKGROUND">Junctional adhesion molecule-A (JAM-A) is an adhesion molecule whose overexpression on breast tumor tissue has been associated with aggressive cancer phenotypes, including human epidermal growth factor receptor-2 (HER2)-positive disease. Since JAM-A has been described to regulate HER2 expression in breast cancer cells, we hypothesized that JAM-dependent stabilization of HER2 could participate in resistance to HER2-targeted therapies.</AbstractText>                <AbstractText Label="METHODS" NlmCategory="METHODS">Using breast cancer cell line models resistant to anti-HER2 drugs, we investigated JAM-A expression and the effect of JAM-A silencing on biochemical/functional parameters. We also tested whether altered JAM-A expression/processing underpinned differences between drug-sensitive and -resistant cells and acted as a biomarker of patients who developed resistance to HER2-targeted therapies.</AbstractText>                <AbstractText Label="RESULTS" NlmCategory="RESULTS">Silencing JAM-A enhanced the anti-proliferative effects of anti-HER2 treatments in trastuzumab- and lapatinib-resistant breast cancer cells and further reduced HER2 protein expression and Akt phosphorylation in drug-treated cells. Increased epidermal growth factor receptor expression observed in drug-resistant models was normalized upon JAM-A silencing. JAM-A was highly expressed in all of a small cohort of HER2-positive patients whose disease recurred following anti-HER2 therapy. High JAM-A expression also correlated with metastatic disease at the time of diagnosis in another patient cohort resistant to trastuzumab therapy. Importantly, cleavage of JAM-A was increased in drug-resistant cell lines in conjunction with increased expression of ADAM-10 and -17 metalloproteases. Pharmacological inhibition or genetic silencing studies suggested a particular role for ADAM-10 in reducing JAM-A cleavage and partially re-sensitizing drug-resistant cells to the anti-proliferative effects of HER2-targeted drugs. Functionally, recombinant cleaved JAM-A enhanced breast cancer cell invasion in vitro and both invasion and proliferation in a semi-in vivo model. Finally, cleaved JAM-A was detectable in the serum of a small cohort of HER2-positive patients and correlated significantly with resistance to HER2-targeted therapy.</AbstractText>                <AbstractText Label="CONCLUSIONS" NlmCategory="CONCLUSIONS">Collectively, our data suggest a novel model whereby increased expression and cleavage of JAM-A drive tumorigenic behavior and act as a biomarker and potential therapeutic target for resistance to HER2-targeted therapies.</AbstractText>            </Abstract>            <AuthorList CompleteYN="Y">                <Author ValidYN="Y">                    <LastName>Leech</LastName>                    <ForeName>Astrid O</ForeName>                    <Initials>AO</Initials>                    <AffiliationInfo>                        <Affiliation>Department of Surgery, Royal College of Surgeons in Ireland, RCSI Education and Research Centre, Beaumont Hospital, Dublin 9, Ireland.</Affiliation>                    </AffiliationInfo>                </Author>                <Author ValidYN="Y">                    <LastName>Vellanki</LastName>                    <ForeName>Sri HariKrishna</ForeName>                    <Initials>SH</Initials>                    <AffiliationInfo>                        <Affiliation>Department of Surgery, Royal College of Surgeons in Ireland, RCSI Education and Research Centre, Beaumont Hospital, Dublin 9, Ireland.</Affiliation>                    </AffiliationInfo>                </Author>                <Author ValidYN="Y">                    <LastName>Rutherford</LastName>                    <ForeName>Emily J</ForeName>                    <Initials>EJ</Initials>                    <AffiliationInfo>                        <Affiliation>Department of Surgery, Royal College of Surgeons in Ireland, RCSI Education and Research Centre, Beaumont Hospital, Dublin 9, Ireland.</Affiliation>                    </AffiliationInfo>                </Author>                <Author ValidYN="Y">                    <LastName>Keogh</LastName>                    <ForeName>Aoife</ForeName>                    <Initials>A</Initials>                    <AffiliationInfo>                        <Affiliation>Department of Surgery, Royal College of Surgeons in Ireland, RCSI Education and Research Centre, Beaumont Hospital, Dublin 9, Ireland.</Affiliation>                    </AffiliationInfo>                </Author>                <Author ValidYN="Y">                    <LastName>Jahns</LastName>                    <ForeName>Hanne</ForeName>                    <Initials>H</Initials>                    <AffiliationInfo>                        <Affiliation>Pathobiology Section, School of Veterinary Medicine, University College Dublin, Belfield, Dublin 4, Ireland.</Affiliation>                    </AffiliationInfo>                </Author>                <Author ValidYN="Y">                    <LastName>Hudson</LastName>                    <ForeName>Lance</ForeName>                    <Initials>L</Initials>                    <AffiliationInfo>                        <Affiliation>Department of Surgery, Royal College of Surgeons in Ireland, RCSI Education and Research Centre, Beaumont Hospital, Dublin 9, Ireland.</Affiliation>                    </AffiliationInfo>                </Author>                <Author ValidYN="Y">                    <LastName>O'Donovan</LastName>                    <ForeName>Norma</ForeName>                    <Initials>N</Initials>                    <AffiliationInfo>                        <Affiliation>National Institute for Cellular Biotechnology, Dublin City University, Collins Avenue, Dublin 9, Ireland.</Affiliation>                    </AffiliationInfo>                </Author>                <Author ValidYN="Y">                    <LastName>Sabri</LastName>                    <ForeName>Siham</ForeName>                    <Initials>S</Initials>                    <AffiliationInfo>                        <Affiliation>Department of Pathology, McGill University, Faculty of Medicine, Department of Pathology, 1001 Decarie Blvd, Montreal, H4A 3J1, QC, Canada.</Affiliation>                    </AffiliationInfo>                </Author>                <Author ValidYN="Y">                    <LastName>Abdulkarim</LastName>                    <ForeName>Bassam</ForeName>                    <Initials>B</Initials>                    <AffiliationInfo>                        <Affiliation>Department of Oncology, McGill University, Faculty of Medicine, Department of Oncology, 1001 Decarie Blvd, Montreal, H4A 3J1, QC, Canada.</Affiliation>                    </AffiliationInfo>                </Author>                <Author ValidYN="Y">                    <LastName>Sheehan</LastName>                    <ForeName>Katherine M</ForeName>                    <Initials>KM</Initials>                    <AffiliationInfo>                        <Affiliation>Department of Pathology, Royal College of Surgeons in Ireland, RCSI Education and Research Centre, Beaumont Hospital, Dublin 9, Ireland.</Affiliation>                    </AffiliationInfo>                </Author>                <Author ValidYN="Y">                    <LastName>Kay</LastName>                    <ForeName>Elaine W</ForeName>                    <Initials>EW</Initials>                    <AffiliationInfo>                        <Affiliation>Department of Pathology, Royal College of Surgeons in Ireland, RCSI Education and Research Centre, Beaumont Hospital, Dublin 9, Ireland.</Affiliation>                    </AffiliationInfo>                </Author>                <Author ValidYN="Y">                    <LastName>Young</LastName>                    <ForeName>Leonie S</ForeName>                    <Initials>LS</Initials>                    <AffiliationInfo>                        <Affiliation>Department of Surgery, Royal College of Surgeons in Ireland, RCSI Education and Research Centre, Beaumont Hospital, Dublin 9, Ireland.</Affiliation>                    </AffiliationInfo>                </Author>                <Author ValidYN="Y">                    <LastName>Hill</LastName>                    <ForeName>Arnold D K</ForeName>                    <Initials>ADK</Initials>                    <AffiliationInfo>                        <Affiliation>Department of Surgery, Royal College of Surgeons in Ireland, RCSI Education and Research Centre, Beaumont Hospital, Dublin 9, Ireland.</Affiliation>                    </AffiliationInfo>                </Author>                <Author ValidYN="Y">                    <LastName>Smith</LastName>                    <ForeName>Yvonne E</ForeName>                    <Initials>YE</Initials>                    <AffiliationInfo>                        <Affiliation>Department of Surgery, Royal College of Surgeons in Ireland, RCSI Education and Research Centre, Beaumont Hospital, Dublin 9, Ireland.</Affiliation>                    </AffiliationInfo>                </Author>                <Author ValidYN="Y">                    <LastName>Hopkins</LastName>                    <ForeName>Ann M</ForeName>                    <Initials>AM</Initials>                    <Identifier Source="ORCID">http://orcid.org/0000-0003-2836-6584</Identifier>                    <AffiliationInfo>                        <Affiliation>Department of Surgery, Royal College of Surgeons in Ireland, RCSI Education and Research Centre, Beaumont Hospital, Dublin 9, Ireland. annhopkins@rcsi.ie.</Affiliation>                    </AffiliationInfo>                </Author>            </AuthorList>            <Language>eng</Language>            <GrantList CompleteYN="Y">                <Grant>                    <GrantID>13/IA/1994</GrantID>                    <Agency>Science Foundation Ireland</Agency>                    <Country>Ireland</Country>                </Grant>                <Grant>                    <GrantID>HRA-POR-2014-545</GrantID>                    <Agency>Health Research Board</Agency>                    <Country>Ireland</Country>                </Grant>            </GrantList>            <PublicationTypeList>                <PublicationType UI="D016428">Journal Article</PublicationType>            </PublicationTypeList>            <ArticleDate DateType="Electronic">                <Year>2018</Year>                <Month>11</Month>                <Day>20</Day>            </ArticleDate>        </Article>        <MedlineJournalInfo>            <Country>England</Country>            <MedlineTA>Breast Cancer Res</MedlineTA>            <NlmUniqueID>100927353</NlmUniqueID>            <ISSNLinking>1465-5411</ISSNLinking>        </MedlineJournalInfo>        <KeywordList Owner="NOTNLM">            <Keyword MajorTopicYN="N">Breast cancer</Keyword>            <Keyword MajorTopicYN="N">Drug resistance</Keyword>            <Keyword MajorTopicYN="N">HER2</Keyword>            <Keyword MajorTopicYN="N">HER2-targeted therapies</Keyword>            <Keyword MajorTopicYN="N">Herceptin</Keyword>            <Keyword MajorTopicYN="N">JAM-A</Keyword>            <Keyword MajorTopicYN="N">Lapatinib</Keyword>            <Keyword MajorTopicYN="N">Tight junction</Keyword>            <Keyword MajorTopicYN="N">Trastuzumab</Keyword>        </KeywordList>    </MedlineCitation>    <PubmedData>        <History>            <PubMedPubDate PubStatus="received">                <Year>2017</Year>                <Month>12</Month>                <Day>21</Day>            </PubMedPubDate>            <PubMedPubDate PubStatus="accepted">                <Year>2018</Year>                <Month>10</Month>                <Day>18</Day>            </PubMedPubDate>            <PubMedPubDate PubStatus="entrez">                <Year>2018</Year>                <Month>11</Month>                <Day>22</Day>                <Hour>6</Hour>                <Minute>0</Minute>            </PubMedPubDate>            <PubMedPubDate PubStatus="pubmed">                <Year>2018</Year>                <Month>11</Month>                <Day>22</Day>                <Hour>6</Hour>                <Minute>0</Minute>            </PubMedPubDate>            <PubMedPubDate PubStatus="medline">                <Year>2018</Year>                <Month>11</Month>                <Day>22</Day>                <Hour>6</Hour>                <Minute>0</Minute>            </PubMedPubDate>        </History>        <PublicationStatus>epublish</PublicationStatus>        <ArticleIdList>            <ArticleId IdType="pubmed">30458861</ArticleId>            <ArticleId IdType="doi">10.1186/s13058-018-1064-1</ArticleId>            <ArticleId IdType="pii">10.1186/s13058-018-1064-1</ArticleId>        </ArticleIdList>    </PubmedData></PubmedArticle></PubmedArticleSet>